期刊
JOURNAL OF RHEUMATOLOGY
卷 46, 期 10, 页码 1316-1325出版社
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.180441
关键词
SYSTEMIC SCLEROSIS; INTERSTITIAL LUNG DISEASE; CYCLOPHOSPHAMIDE
类别
资金
- US National Heart, Lung, and Blood Institute/National Institutes of Health (NIH) [R01 HL089758, R01 HL089901]
- NIH/National Center for Advancing Translational Science, University of California, Los Angeles CTSI [UL1TR000124]
- Scleroderma Foundation
- Rheumatology Research Foundation
Objective. To compare safety and efficacy outcomes between the cyclophosphamide (CYC) arms of Scleroderma Lung Study (SLS) I and II. Methods. Participants enrolled in the CYC arms of SLS I (n = 79) and II (n = 69) were included. SLS I and II randomized participants to oral CYC for 1 year and followed patients for an additional year off therapy (in SLS II, patients received placebo in Year 2). Eligibility criteria for SLS I and II were nearly identical. Outcomes included the forced vital capacity (FVC%)-predicted and DLCO%-predicted (measured every 3 mos) and quantitative radiographic extent of interstitial lung disease (measured at 1 and 2 yrs for SLS I and SLS II, respectively). Joint models were created to evaluate the treatment effect on the course of the FVC/DLCO over 2 years while controlling for baseline disease severity. Results. SLS I and II CYC participants had similar baseline characteristics. After adjusting for baseline disease severity, there was no difference in the course of the FVC%-predicted (p = 0.535) nor the DLCO%-predicted (p = 0.172) between the SLS I and II CYC arms. In both groups, treatment with CYC led to a significant improvement in the FVC%-predicted from 3 to 12 months, but no significant improvement beyond this point. Treatment with CYC had no effect on the DLCO for either group. Conclusion. Treatment with 1 year of oral CYC led to similar improvements in lung function in both SLS I and II, although the effects were not sustained following cessation of CYC. These results suggest that increasing the duration of ILD therapy may improve outcomes for patients with systemic sclerosis ILD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据